Meeting
2022 ASCO Genitourinary Cancers Symposium
Immune profiling of advanced prostate cancer harboring homologous recombination deficiency.
Authors
Maryam Soleimani
BC Cancer, Vancouver, BC, Canada
Maryam Soleimani , Sonia H.Y. Kung , Neetu Saxena , Marisa Thi , Ladan Fazli , Lucia Nappi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Translational Research, Tumor Biology, Biomarkers, and Pathology
Citation
J Clin Oncol 40, 2022 (suppl 6; abstr 163)
DOI
10.1200/JCO.2022.40.6_suppl.163
Abstract #
163
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Prevalence of homologous recombination deficiency (HRD) mutations in localized prostate cancer according to Gleason grade: Implications for neoadjuvant clinical trial design.
First Author: Catherine Handy
Poster
2022 ASCO Genitourinary Cancers Symposium
Identification of homologous recombination and repair (HRR) deficiency using circulating tumor DNA (ctDNA) in advanced prostate cancer (aPC).
First Author: Leslie A. Bucheit
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Homologous recombination repair pathway alterations and their relationship to homologous recombination deficiency in advanced pancreatic cancer patients.
First Author: Hitendra Patel
Poster
2023 ASCO Annual Meeting
The spectrum of homologous recombination deficiency in cervical cancer: Is it also a cervical issue?
First Author: Muhammad Danyal Ahsan